Phase 3 N=408 Randomized Safety Study of CVT-301 Compared to an Observational Control Group
Idiopathic Parkinson's Disease
Primary: Pulmonary Safety Assessed by Forced Expiratory Volume in 1 Second [FEV1] — 2.778; 2.767 Liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates
Thromboembolism
Primary: Concentration of Rivaroxaban in Plasma as a Measure of Pharmacokinetics at Day 1 — 85.2001; 42.6837; 73.7641; 12.1027 microgram per liter (mcg/L)
Phase 2 N=483 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Migraine
Primary: Change From Baseline in Monthly Migraine Days at Week 12 — -2.28; -2.18; -2.39; -3.40 migraine days / month — p=0.021
Phase 2 N=158 A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response up to 24 Weeks — 18.1; 17.7; 17.0; 15.0 percentage of participants — p=0.059
N/A N=27 Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain
Post-Operative Pain
Primary: Patient Controlled Analgesia (PCA) Hydromorphone Usage — 12.6; 16.5 milligrams of hydromorphone
Phase 3 N=955 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention
Migraine
Primary: Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period — -1.83; -3.23; -3.67 migraine days / month — p=< 0.001
Phase 2 N=27 Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)
Hypophosphatasia
Primary: Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9 — -2.604; -3.797; -4.484 μM — p=<0.0001
Phase 2 N=24 TPI 287 in Breast Cancer Metastatic to the Brain
Breast Cancer
Primary: Overall Response Rate (ORR) — 21 Participants
Phase 4 N=46 Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women
Insulin Sensitivity · Cardiovascular Risk · Perimenopausal Disorder
Primary: Change From Baseline in Insulin Sensitivity — -1.91; -5.63 min ^ -1 / mIU / L
N/A N=40 TAME Health: Testing Activity Monitors' Effect on Health
Physical Activity
Primary: Physical Activity Minutes Measured by a SenseWear Armband — 40.2; 33.8 minutes per day
Phase 1 N=14 Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Maximum Analyte Plasma Concentration (Cmax) — 2.44; 1.61 ng/mL
Phase 4 N=304 A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline to 12 Weeks in the Weekly Mean of the 24-Hour Average Pain Score on the 11-Point Numeric Rating Scale (NRS) — -2.358; -2.286 units on a scale…
Phase 2 N=45 Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple…
Phase 4 N=8 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Assess the Mean Area Under the Curve (AUC) for Blood Glucose Concentration in Subjects Treated With Pramlintide + Insulin, Compared to Insulin Alone — 205; 993 mmol*L/min
Phase 2 N=45 Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Aplastic Anemia · Leukemia · Myelodysplastic Syndrome
Primary: Successful Neutrophil Engraftment — 44; 1 Participants